DPP4 and neoplasm: In the current study, we sought to determine whether DPP4 inhibition using sitagliptin enhances lymphocyte tumour infiltration in a syngeneic mouse model of EOC [22] to abrogate tumour-mediated immune suppression and promote antitumour immunity.